A new approach to treatment of heart failure started by guanylate cyclase stimulator combined with RAS inhibitors
-
摘要: 心力衰竭时,细胞内NO-sGC-cGMP信号通路被削弱,肾素-血管紧张素系统(RAS)异常激活参与调控cGMP/PKG信号,损害心脏功能。可溶性鸟苷酸环化酶(sGC)刺激剂是一种作用于细胞内NO-sGC-cGMP信号通路的新型药物。临床试验与动物实验均证明,在RAS阻滞剂基础上加用sGC刺激剂治疗心力衰竭,可以有效改善心脏和肾脏功能,为心力衰竭治疗提供了一条新途径。
-
关键词:
- 心力衰竭 /
- 可溶性鸟苷酸环化酶刺激剂 /
- NO-sGC-cGMP信号通路
Abstract: During the progression of heart failure, the intracellular NO-sGC-cGMP pathway is suppressed, while the renin-angiotensin system(RAS) is abnormally activated and involved in the regulation of cGMP/PKG signal transduction, impairing cardiac function. Soluble guanylate cyclase(sGC) stimulant is currently a novel drug targeting the NO-sGC-cGMP signaling pathway. Clinical trials and animal experiments have proved that the treatment of heart failure with sGC stimulant, based on the use of RAS inhibitors, can effectively improve cardiac and renal function, which then provides a new way to manage this syndrome.-
Key words:
- heart failure /
- soluble guanylate cyclase stimulant /
- NO-sGC-cGMP pathway
-
-
[1] Global,regional,and national incidence,prevalence,and years lived with disability for 354 diseases and injuries for 195 countries and territories,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2018,392(10159):1789-1858.
[2] Ambrosy AP,Fonarow GC,Butler J,et al.The global health and economic burden of hospitalizations for heart failure:lessons learned from hospitalized heart failure registries[J].J Am Coll Cardiol,2014,63(12):1123-1133.
[3] Murphy SP,Kakkar R,McCarthy CP,et al.Inflammation in heart failure:JACC State-of-the-Art Review[J].J Am Coll Cardiol,2020,75(11):1324-1340.
[4] Tanai E,Frantz S.Pathophysiology of heart failure[J].Compr Physiol,2015,6(1):187-214.
[5] 中国心衰中心联盟.舒张性心力衰竭早期防治专家建议[J].临床心血管病杂志,2021,37(1):1-6.
[6] Kong Q,Blanton RM.Protein kinase G I and heart failure:Shifting focus from vascular unloading to direct myocardial antiremodeling effects[J].Circ Heart Fail,2013,6(6):1268-1283.
[7] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心力衰竭和心肌病杂志,2018,2(4):196-225.
[8] Writing Committee,Maddox TM,Januzzi JL Jr,et al.2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment:Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction:A Report of the American College of Cardiology Solution Set Oversight Committee[J].J Am Coll Cardiol,2021,77(6):772-810.
[9] Gheorghiade M,Marti CN,Sabbah HN,et al.Soluble guanylate cyclase:a potential therapeutic target for heart failure[J].Heart Fail Rev,2013,18(2):123-134.
[10] Breitenstein S,Roessig L,Sandner P,et al.Novel sGC stimulators and sGC activators for the treatment of heart failure[J].Handb Exp Pharmacol,2017,243:225-247.
[11] Evgenov OV,Pacher P,Schmidt PM,et al.NO-independent stimulators and activators of soluble guanylate cyclase:discovery and therapeutic potential[J].Nat Rev Drug Discov,2006,5(9):755-768.
[12] Wiemer G,Itter G,Malinski T,et al.Decreased nitric oxide availability in normotensive and hypertensive rats with failing hearts after myocardial infarction[J].Hypertension,2001,38(6):1367-1371.
[13] Katz SD,Khan T,Zeballos GA,et al.Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure[J].Circulation,1999,99(16):2113-2117.
[14] van Heerebeek L,Hamdani N,Falcao-Pires I,et al.Low myocardial protein kinase G activity in heart failure with preserved ejection fraction[J].Circulation,2012,126(7):830-839.
[15] Pacher P,Beckman JS,Liaudet L.Nitric oxide and peroxynitrite in health and disease[J].Physiol Rev,2007,87(1):315-424.
[16] Münzel T,Steven S,Daiber A.Organic nitrates:update on mechanisms underlying vasodilation,tolerance and endothelial dysfunction[J].Vascul Pharmacol,2014,63(3):105-113.
[17] Packer M,Lee WH,Kessler PD,et al.Prevention and reversal of nitrate tolerance in patients with congestive heart failure[J].N Engl J Med,1987,317(13):799-804.
[18] Nakamura T,Zhu G,Ranek MJ,et al.Prevention of PKG-1α oxidation suppresses antihypertrophic/antifibrotic effects from PDE5 inhibition but not sGC stimulation[J].Circ Heart Fail,2018,11(3):e004740.
[19] Pellicena P,Karow DS,Boon EM,et al.Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases[J].Proc Natl Acad Sci U S A,2004,101(35):12854-12859.
[20] Follmann M,Ackerstaff J,Redlich G,et al.Discovery of the soluble guanylate cyclase stimulator vericiguat(BAY 1021189) for the treatment of chronic heart failure[J].J Med Chem,2017,60(12):5146-5161.
[21] Follmann M,Griebenow N,Hahn MG,et al.The chemistry and biology of soluble guanylate cyclase stimulators and activators[J].Angew Chem Int Ed Engl,2013,52(36):9442-9462.
[22] Sandner P.From molecules to patients:exploring the therapeutic role of soluble guanylate cyclase stimulators[J].Biol Chem,2018,399(7):679-690.
[23] Theilig F,Bostanjoglo M,Pavenstadt H,et al.Cellular distribution and function of soluble guanylyl cyclase in rat kidney and liver[J].J Am Soc Nephrol,2001,12(11):2209-2220.
[24] Behrends S,Mietens A,Kempfert J,et al.The expression pattern of nitric oxide-sensitive guanylyl cyclase in the rat heart changes during postnatal development[J].J Histochem Cytochem,2002,50(10):1325-1332.
[25] Rüdebusch J,Benkner A,Nath N,et al.Stimulation of soluble guanylyl cyclase(sGC)by riociguat attenuates heart failure and pathological cardiac remodelling[J].Br J Pharmacol,2020.
[26] Gonzaga-Costa K,Roque CR,Vasconcelos-Silva AA,et al.The soluble guanylate cyclase stimulator,1-nitro-2-phenylethane,reverses monocrotaline-induced pulmonary arterial hypertension in rats[J].Life Sci,2021,275:119334.
[27] Sharkovska Y,Kalk P,Lawrenz B,et al.Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models[J].J Hypertens,2010,28(8):1666-1675.
[28] Zhang F,Xu Y,Pan Y,et al.Effects of angiotensin-(1-7) and angiotensin II on acetylcholine-induced vascular relaxation in spontaneously hypertensive rats[J].Oxid Med Cell Longev,2019,2019:6512485.
[29] Yan C,Kim D,Aizawa T,et al.Functional interplay between angiotensin II and nitric oxide:cyclic GMP as a key mediator[J].Arterioscler Thromb Vasc Biol,2003,23(1):26-36.
[30] Savoia C,Ebrahimian T,He Y,et al.Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase[J].J Hypertens,2006,24(12):2417-2422.
[31] Fraccarollo D,Galuppo P,Motschenbacher S,et al.Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction.Cardioprotection over ACE inhibition[J].Basic Res Cardiol,2014,109(4):421.
[32] Tobin JV,Zimmer DP,Shea C,et al.Pharmacological characterization of IW-1973,a novel soluble guanylate cyclase stimulator with extensive tissue distribution,antihypertensive,anti-inflammatory,and antifibrotic effects in preclinical models of disease[J].J Pharmacol Exp Ther,2018,365(3):664-675.
[33] Liu G,Shea CM,Jones JE,et al.Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells[J].Am J Physiol Renal Physiol,2020,319(4):F697-F711.
[34] Ott IM,Alter ML,von Websky K,et al.Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade[J].PLoS One,2012,7(8):e42623.
[35] Bonderman D,Pretsch I,Steringer-Mascherbauer R,et al.Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure(DILATE-1):a randomized,double-blind,placebo-controlled,single-dose study[J].Chest,2014,146(5):1274-1285.
[36] Armstrong PW,Roessig L,Patel MJ,et al.A multicenter,randomized,double-blind,placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator:The VICTORIA Trial[J].JACC Heart Fail,2018,6(2):96-104.
[37] Armstrong PW,Pieske B,Anstrom KJ,et al.Vericiguat in patients with heart failure and reduced ejection fraction[J].N Engl J Med,2020,382(20):1883-1893.
-
计量
- 文章访问数: 297
- PDF下载数: 1107
- 施引文献: 0
下载: